From an article by Scott Wagers MD:
A challenge that anyone working to bring new technology, therapies, or approaches from proof of concept to clinic implementation is funding. I have been tracking the concept of crowd funding for a number of years, but have not seen many platforms that offer the opportunity to raise funding to a degree that will really make a difference.
So, I was enthusiastic when I met Pilar Puig Sàrries and learned about the work she is doing at Capital Cell, a crowdfunding platform specializing in the life sciences. She is the head the BioExpert Network and life sciences analytics at Capital Cell and passionate about her work to help startups in the life sciences bridge the translational gap.
How did you start doing what you are doing now?
During my PhD in molecular biology I felt uncertain about becoming a Spanish researcher because in Spain every 1-3 years you need to apply for further support for your research which means no stability.
So, during my PhD I began my first startup. It was an online/offline game for couples. I was able to sell 1.000 games after closing a successful crowdfunding campaign, which in my mind was pretty successful. But I also had to write my thesis and I also had a big interest in travel.
After my PhD I took a 9 month trip to South America and those 9 months were the happiest time of my life. When I came back, I knew that I didn’t want to keep doing research, so it seemed ideal to do something related to science, but also related to entrepreneurship. I was fortunate to find an opportunity at Capital Cell as a life science analyst.
What do you do at Capital Cell?
Capital cell is a start-up which means anyone working there has many roles. My job title is life science analyst, but I also do business development for clients such as helping them with their business models and building their pitch. We also help them look for investors as well. I also produce content for the website. Last year with the CEO of Capital Cell we created the BioExpert Network which is a network of experts who help us evaluate and select companies to be included in our crowdfunding platform.
Can you explain a bit about the philosophy behind Capital Cell and how it works?
Capital Cell is the first equity crowdfunding specialized in life sciences in Europe. And since last September, we are also operating in the UK.
We help companies in the life science sector get funded. Most of them are in the ‘valley of death’, which is also called the translational gap. They may have proof of concept, but need capital to continue to get scientific validation. We are now working with some companies that are further along, but still need to have some more funding before approaching VCs.
Image Credit: Shutterstock.com
News This Week
The Global Nanomedicine Market: Key Players and Emerging Technologies in Healthcare
This article provides an overview of the global nanomedicine market, highlighting key players, emerging technologies, and the challenges and opportunities that influence its growth and commercialization in the healthcare sector. Nanomedicines are nanotechnology-based drug products [...]
Scientists Have Discovered Toxic “Forever Chemicals” in Bottled Water
Scientists have found toxic PFAS in drinking water samples from around the world, with higher levels in tap water from China compared to the UK. Boiling water or using a filtration jug can reduce [...]
Urban Microbes Are Eating Disinfectants – Are We Fueling a New Health Threat?
New research reveals that microbes in urban environments are evolving to withstand the very cleaning agents designed to eliminate them. The study also uncovers new strains in Hong Kong, previously only found in the [...]
Startling Study Shows High-Potency Cannabis Alters DNA
The study shows that frequent use of high-potency cannabis alters DNA, affecting genes related to energy and immune function. These changes differ between those with and without psychosis, suggesting cannabis use could influence mental health through biological [...]
New nanotherapy targets artery inflammation in cardiovascular disease
Inflammation of the arteries is a primary precursor and driver of cardiovascular disease—the No. 1 killer of people in the United States. This inflammation is associated with the buildup of dangerous plaque inside the [...]
Revolutionary Nanoparticle Therapy for Prostate Cancer
A groundbreaking research effort involving teams from the University of Virginia, Mount Sinai, the University of Michigan, the University of Texas, and others has displayed the clinical efficacy of an innovative therapy that utilizes nanoparticles and [...]
Antibody engineering drives innovation in drug development
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound [...]
Breakthrough Study Reveals How Bladder Cancer Starts and Spreads
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal circular DNA in tumor cells drives resistance to therapy. These discoveries open new therapeutic avenues. A groundbreaking study led by [...]
Leave A Comment